Meeting
2017 Gastrointestinal Cancers Symposium
NESC multicenter phase II trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel-cisplatin-5FU + lenograstim) followed by chemoradiation (RTCT) based 5FU and oxaliplatin and surgery.
Authors
Laurent Mineur
Institut Sainte-Catherine, Avignon, France
Laurent Mineur , Gael Deplanque , Francoise Desseigne , Laurence Moureau-Zabotto , Olivier Boulat , Khadifa Jalali , Denis Michel Smith , Stephane Obled , Mohamed Belkacemi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01565109
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 95)
DOI
10.1200/JCO.2017.35.4_suppl.95
Abstract #
95
Poster Bd #
H7
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of nanosomal docetaxel lipid suspension (NDLS) in patients with advanced gastric adenocarcinoma.
First Author: Vikas S. Ostwal
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2020 Gastrointestinal Cancers Symposium
Phase II study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic ductal adenocarcinoma.
First Author: Emerson Yu-sheng Chen
Poster
2020 Gastrointestinal Cancers Symposium
Survival benefit of conversion therapy after intensive chemotherapy for unresectable metastatic gastric cancer: A propensity score-matched analysis.
First Author: Hiroyuki Ohnuma